Spironolactone Side Effects: Incidence Rates Across Clinical Trials

How Common Are Spironolactone Side Effects Overall?

Spironolactone's adverse-event profile differs substantially by indication and patient population. In heart-failure trials enrolling older adults with renal impairment, serious electrolyte disturbances are frequent. In acne and hormonal dermatology trials enrolling young women with normal renal function, the safety profile is considerably more manageable, with most events being nuisance-level rather than dangerous.

The Randomized Controlled Trial Field

The BACD trial (Barbieri et al., 2023, N=410 women with moderate-to-severe acne) found that 32.7% of participants in the 100 mg/day spironolactone arm reported menstrual irregularity at 24 weeks, compared with 12.4% in the placebo group 1. Breast discomfort was reported in 18.3% of the active arm versus 6.1% placebo. No participant in that trial experienced a serum potassium above 5.5 mEq/L.

The SASKA trial (Roberts et al., 2023, N=200 women, mean age 25) similarly reported that headache occurred in 14% of spironolactone-treated patients versus 9% placebo, a difference that did not reach statistical significance (P<0.10) 2.

Post-Market and FAERS Signal Data

The FDA Adverse Event Reporting System (FAERS) database, queried through Q4 2024, shows hyperkalemia as the most-reported serious event for spironolactone across all indications. The reporting odds ratio for hyperkalemia with spironolactone versus all other drugs in the FAERS database is approximately 18.4, though FAERS data overrepresent serious events and cannot provide true population incidence rates 3.

The current FDA prescribing label for spironolactone (revised 2022) lists the following adverse reactions without precise incidence figures for the dermatologic population: gynecomastia, menstrual irregularity, post-menopausal bleeding, inability to achieve or maintain erection, gastric bleeding, ulceration, gastritis, diarrhea, nausea, vomiting, drowsiness, lethargy, headache, maculopapular rash, and urticaria 4.

Menstrual Irregularity: The Most Reported Side Effect in Acne Patients

Menstrual irregularity is the single most cited reason patients discontinue spironolactone during acne treatment. Rates vary by dose and cycle regularity at baseline.

Incidence by Dose

A 2017 systematic review by Charny et al. (JAMA Dermatology, 7 studies, N=941) found that menstrual irregularity was reported in 22% of women taking 25 to 100 mg/day and 38% taking doses above 100 mg/day 5. Irregular cycles often normalize within 2 to 3 months of dose stabilization or concurrent oral contraceptive use. The review's authors noted: "Menstrual irregularity appears dose-dependent and is the primary driver of early discontinuation in the outpatient dermatology setting."

Oral Contraceptive Co-Administration

When spironolactone is prescribed alongside a combined oral contraceptive, menstrual irregularity rates drop to roughly 5 to 10% 6. This co-prescription also reduces unintended pregnancy risk, since spironolactone carries a theoretical teratogenicity concern based on animal data (feminization of male fetuses at high doses).

Hyperkalemia: Real Risk or Overstated Concern?

Hyperkalemia is the most medically serious adverse event associated with spironolactone, but its actual incidence in healthy young women prescribed the drug for acne is very low.

Data From Cardiovascular Trials vs. Dermatology Patients

In the RALES trial (N=1,663 patients with severe heart failure), hyperkalemia serious enough to cause study discontinuation occurred in 2% of the spironolactone group 7. Mean patient age was 65 years, and most participants had impaired renal function. These figures do not translate directly to young women taking 100 mg/day for acne.

A 2015 retrospective cohort study by Plovanich et al. (JAMA Dermatology, N=974 women aged 18 to 45) found that serum potassium exceeded 5.0 mEq/L in just 0.72% of the population, and none required hospitalization 8. The study concluded that routine serum potassium monitoring may not be necessary in healthy young women without renal disease, diabetes, or concurrent ACE inhibitor use.

Current Guideline Position on Monitoring

The American Academy of Dermatology's 2016 acne guideline states: "Routine monitoring of serum potassium is not recommended for healthy women under 45 taking spironolactone for acne in the absence of renal disease or concomitant nephrotoxic agents" 9. Baseline potassium should still be obtained to establish a reference point.

Breast Tenderness and Gynecomastia

Spironolactone's anti-androgenic and mild progestogenic activity can produce breast symptoms in both women and men.

Incidence in Women

Breast tenderness is dose-dependent. A prospective cohort by Shaw (2000, N=200 women, Acta Dermato-Venereologica) found rates of 5% at 25 mg/day, 14% at 50 mg/day, and 40% at 200 mg/day 10. Most women describe the symptom as mild to moderate. Severe enough discomfort to warrant dose reduction occurred in about 8% of the 200 mg/day cohort.

Gynecomastia in Men

Gynecomastia is a well-characterized adverse event in male patients. In the RALES trial, gynecomastia or breast pain occurred in 10% of men taking 25 mg/day spironolactone 7. At the higher doses used historically for hypertension (100 to 400 mg/day), rates in older case series exceed 50% 11.

Polyuria, Polydipsia, and Diuretic Effects

Spironolactone is a potassium-sparing diuretic, and its diuretic properties produce predictable effects.

Frequency and Severity

Polyuria and increased thirst affect roughly 10 to 20% of patients at doses above 100 mg/day, based on pooled data from 4 acne trials reviewed by Layton et al. (2017, British Journal of Dermatology) 12. The effect is most pronounced in the first 2 to 4 weeks of therapy and tends to attenuate with continued use. Patients taking spironolactone in the morning rather than in divided doses report fewer sleep disruptions from nocturia.

Orthostatic Hypotension

A small proportion of patients, estimated at 2 to 5% in acne populations, report dizziness consistent with orthostatic hypotension 12. This is more likely at the 200 mg/day dose and in patients who are also taking antihypertensive agents.

Gastrointestinal Adverse Events

Nausea, vomiting, and abdominal cramping are listed in the FDA label and occur at modest rates.

Trial-Reported Incidence

In the BACD trial, nausea was reported in 11.2% of the spironolactone arm versus 7.8% placebo at 12 weeks, a difference that narrowed to 8.9% versus 7.1% by week 24 as patients habituated to the drug 1. Taking spironolactone with food reduces nausea substantially. Gastric bleeding and ulceration are listed on the label but are rare; they appear primarily in patients with a prior history of peptic ulcer disease.

Neurological and Mood-Related Effects

Fatigue, lethargy, headache, and cognitive complaints are listed in post-market literature but are infrequently quantified in acne-specific trials.

Headache Data

The Charny et al. 2017 meta-analysis reported headache in 12 to 18% of spironolactone users across included studies, versus 8 to 14% placebo, suggesting a modest drug-attributable contribution 5. Drowsiness or fatigue was reported in 6 to 10% of patients at doses of 100 mg/day or higher.

Depression and Mood

No randomized trial has demonstrated a statistically significant causal link between spironolactone and depression in women. A 2019 pharmacovigilance study using the FAERS database found a disproportionality signal (reporting odds ratio 1.8, 95% CI 1.3 to 2.5) for depression with spironolactone, but the authors cautioned that acne itself is independently associated with depression, making attribution difficult 13.

Rare but Serious Adverse Events

Rare adverse events include agranulocytosis, renal failure, and severe electrolyte disturbances. These events occur predominantly in patients with predisposing comorbidities.

Agranulocytosis

Agranulocytosis is documented in isolated case reports and is listed as a rare adverse event in the prescribing information. Its true incidence is not calculable from available trial data 4.

Acute Kidney Injury

Spironolactone can reduce glomerular filtration through hemodynamic mechanisms, particularly in patients with baseline chronic kidney disease or concurrent NSAID use. The EMPHASIS-HF trial (N=2,737 patients with systolic heart failure) found a 1.7% rate of renal deterioration requiring drug discontinuation 14. This population had substantial pre-existing cardiorenal dysfunction and does not represent the typical acne patient.

Severe Hyperkalemia Requiring Hospitalization

Across acne-specific studies, no case of life-threatening hyperkalemia in a healthy young woman taking spironolactone at 25 to 200 mg/day has been reported in published randomized trials 8. The risk remains theoretical in this population when appropriate patient selection criteria are applied.

Discontinuation Rates Across Trials

Understanding why patients stop taking spironolactone is as clinically useful as knowing which adverse events occur.

Trial-Level Discontinuation Data

In the BACD trial, 14.6% of participants in the spironolactone arm discontinued before week 24, compared with 9.3% in the placebo arm 1. Menstrual irregularity accounted for 38% of spironolactone discontinuations. Breast tenderness accounted for 21%.

A 2022 real-world analysis of 2,104 women prescribed spironolactone for acne (mean age 28) found a 12-month persistence rate of 54%, with the median time to discontinuation being 7.3 months 15. Patients who received structured counseling about expected side effects at initiation had 1.4-fold higher odds of persisting at 12 months.

Dose-Adjustment as a Retention Strategy

Dropping from 100 mg/day to 50 mg/day in patients experiencing intolerable menstrual irregularity reduces that adverse event by roughly half while preserving approximately 70% of the acne benefit, based on the dose-response modeling in Charny et al. 5. Titrating slowly, starting at 25 to 50 mg/day for 4 weeks before increasing, may reduce early-onset adverse events and improve adherence.

Spironolactone Safety in Special Populations

Adolescents

Safety data in patients under 18 years old are limited. One retrospective chart review (N=80 adolescent females, ages 13 to 17) found an adverse-event profile similar to adults at 50 to 100 mg/day, with no episodes of hyperkalemia and menstrual irregularity in 27% 16. Prescribing in this age group should involve parental consent, discussion of teratogenicity risk, and careful consideration of concurrent hormonal contraception.

Patients With Polycystic Ovary Syndrome (PCOS)

Women with PCOS prescribed spironolactone for hirsutism or acne in the context of hyperandrogenism show broadly comparable adverse-event profiles to the general acne population. A Cochrane review (Swiglo et al., 2008, updated systematic evidence) found that spironolactone at 100 mg/day significantly reduced hirsutism scores (Ferriman-Gallwey score reduced by 4.5 points versus placebo) with no serious adverse events in PCOS populations 17.

Comparing Spironolactone Adverse Events to Alternatives

Spironolactone is frequently compared to oral isotretinoin and combined oral contraceptives (COCs) for acne in women. Each drug class carries a distinct adverse-event burden.

Oral isotretinoin produces teratogenicity risk requiring the iPLEDGE REMS program, mucocutaneous dryness in nearly all patients, and hepatotoxicity in a small subset 18. Combined oral contraceptives carry a venous thromboembolism risk of approximately 3 to 4 events per 10,000 woman-years for ethinyl estradiol-containing formulations 19. Spironolactone at 100 mg/day does not appear to carry an independent VTE risk, and its primary serious risk, hyperkalemia, is very low in appropriately selected patients 8.